3B BlackBio Dx Schedules Nov 13 Board Meeting for Q2 FY27 Results

3B BlackBio Dx Limited will hold its board meeting on November 13, 2026, at 3:00 PM to consider unaudited standalone and consolidated Q2 and H1 FY27 results, following Q1 consolidated revenue growth of 50.65% year-on-year to ₹33.49 crore. The announcement matters because investors will assess whether revenue growth can translate into improved profitability after Q1 profit declined.

When will 3B BlackBio Dx consider its Q2 FY27 results?

3B BlackBio Dx will consider and approve its unaudited standalone and consolidated financial results for the quarter and half-year ended in FY27 at a board meeting scheduled for Friday, November 13, 2026, at 3:00 PM. The company manufactures and sells molecular diagnostic kits in India.

The scheduled meeting is the next formal financial update after the company reported its June 2026 quarter results on August 13, 2026. The board will review both standalone performance and consolidated performance, which includes the contribution of CORIS.

The intimation does not disclose the Q2 financial numbers in advance. As a result, the November 13 announcement will be the source for updated revenue, profitability, margin and operating-performance figures for the second quarter and first half of FY27.

For shareholders, the release will also provide a basis to compare the latest quarter with the June 2026 quarter, when sales declined sequentially but remained substantially higher than the prior-year period. The company has previously indicated that its FY27 focus includes domestic diagnostics, exports and global expansion.

What did 3B BlackBio Dx report in Q1 FY27?

3B BlackBio Dx reported consolidated revenue of ₹33.49 crore for the quarter ended June 30, 2026, up 50.65% from ₹22.23 crore a year earlier, while profit after tax fell 28.99% to ₹8.98 crore from ₹12.64 crore. Earnings per share declined to ₹10.48 from ₹14.76 in the corresponding previous-year quarter.

The difference between revenue growth and profit movement reflected higher expenses and a lower profit margin. The reported net profit margin was 24%, compared with 57% in the corresponding prior-year quarter. The company also reported that CORIS contributed sales of ₹8.63 crore during Q1 FY27 and recorded negative EBITDA of ₹3.52 crore.

On a sequential basis, June-quarter net sales were lower than ₹35.43 crore in March 2026. Profit after tax also declined from ₹9.80 crore in the March quarter. However, operating profit improved marginally to ₹8.52 crore from ₹8.49 crore, with operating profit margin rising to 25.44% from 23.96% sequentially.

Why did Q1 profit decline despite higher revenue?

Profit declined in Q1 FY27 because expenses increased, reducing margins despite the sharp increase in revenue. The available results summary specifically attributes the lower margin to higher expenses, while the consolidated result also included a negative EBITDA contribution from CORIS.

Total expenses in the June 2026 quarter were ₹24.97 crore, compared with ₹10.40 crore in the June 2025 quarter. At the same time, other income was ₹6.14 crore, lower than ₹10.15 crore in the March 2026 quarter. These movements are relevant when comparing profit figures across quarters.

The June 2026 quarter followed a period of uneven quarterly sales. Net sales were ₹50.35 crore in December 2025, ₹33.90 crore in September 2025 and ₹35.43 crore in March 2026, according to the reported quarterly data. This makes the forthcoming Q2 disclosure important for tracking the company’s revenue progression beyond a single quarter.

The Q1 result was also the first cited comparative period to include CORIS, while the Q1 FY26 figures did not include CORIS. Comparisons of consolidated profitability therefore need to account for the acquired business’s reported sales contribution and negative EBITDA.

What guidance has 3B BlackBio Dx provided for FY27?

3B BlackBio Dx has guided for consolidated revenue growth of 15% to 20% in FY27, with operating profit growth expected to follow the revenue-growth trajectory. Management provided this guidance during its call on June 1, 2026, covering expectations for the financial year.

The company expects domestic 3B India growth of 10% to 12% and export growth of 20% to 25%, producing blended consolidated growth of 15% to 20%. It has cited expansion across Europe, Africa, Asia Pacific, the Middle East and Latin America as part of its growth focus.

For CORIS, management expects the business to be slightly operating-profit positive for the full year FY27. It has indicated a target of 5% to 10% margin progression in FY28, with margins above 10% targeted in subsequent years. These are management targets rather than reported financial results.

The company’s balance sheet was described as having near-negligible debt of about ₹3 crore alongside treasury cash and investment reserves. The reported financial position is relevant as 3B BlackBio Dx pursues operations and expansion across its diagnostic businesses.

How could the Q2 release matter for investors and the diagnostics business?

The Q2 release will matter because it will show whether 3B BlackBio Dx is maintaining revenue momentum while controlling costs and progressing towards its stated operating-profit objectives. Investors will be able to compare the reported figures with the 15% to 20% FY27 revenue-growth guidance and with the June-quarter margin profile.

The result will also clarify the latest consolidated contribution from CORIS. In Q1 FY27, CORIS sales were ₹8.63 crore and EBITDA was negative ₹3.52 crore. Updated figures can indicate how the business is performing against management’s expectation of full-year operating-profit positivity.

For the molecular diagnostics sector, the company’s domestic growth and export targets provide context for its financial updates. The company has indicated that it is pursuing regulatory progress and an US FDA submission for antimicrobial resistance products, although the board-meeting notice itself is limited to the approval of financial results.

No new financial outcome should be inferred before the board considers the results. The scheduled announcement, rather than the meeting intimation, will establish the company’s reported Q2 and H1 FY27 financial performance.

Conclusion

3B BlackBio Dx’s November 13 board meeting is a scheduled corporate event that will provide the first official view of Q2 and H1 FY27 performance. The key recent financial contrast is clear: Q1 consolidated revenue increased 50.65% year-on-year to ₹33.49 crore, while profit after tax declined 28.99% to ₹8.98 crore as expenses rose and margins narrowed.

Investors will watch the disclosed Q2 revenue, operating margins, profit after tax and CORIS performance against management’s FY27 target of 15% to 20% growth in revenue and operating profit. The results will also be relevant to the company’s stated aim for CORIS to become operating-profit positive during FY27.